In an early 2019 report, commercial real estate giant CBRE Group pointed to Chicago as a Top 10 center of life sciences investment, noting the city’s high-quality science, medicine and business talent pool, increasing access to venture capital and nationally ranked research universities and health systems.
In fact, 1 in 10 U.S. computer science degrees is now produced at an Illinois college or university – and a recent LinkedIn analysis showed that those new grads are five times more likely to work in Chicago than any other city in the country.
Jeff Aronin, Chairman and CEO of Paragon Bio-sciences thinks these are promising trends for bio-pharma and biotech growth in the city of Chicago, particularly as life sciences and data skills continue to intersect throughout healthcare.
At a recent Tales from the Trenches” session at MATTER, the healthcare incubator based at Chicago’s Merchandise Mart, Jeff Aronin said, “I think we have all the pieces, great research, great institutions. The big pharma talent that’s here is as good as anywhere in the country — that’s critical.”
In a separate report, CBRE said Chicago’s overall technology labor pool is now the sixth largest in the country, growing more than 10 percent in the last six years alone. Crediting “a robust infusion of various capital sources, and a more seasoned pool of serial tech leadership, the city has become a powerful magnet for tech talent and businesses alike seeking a top tier global city that still maintains an affordable cost of living.”